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Harnessing Viral Devices Minireview
as Pharmaceuticals: Fighting
HIV-1's Fire with Fire
Garry P. Nolan the delivered ªdrugº creates more copies of itself within
the HIV-1 cells targeted for destruction and then movesDepartment of Molecular Pharmacology
Department of Microbiology and Immunology on to seek out other HIV-1 infected cells, killing them in
turn. The approach resulted in a significant suppressionStanford University School of Medicine
Stanford, California 94305 of HIV-1 replication for over 30 days in the test tube in
what appeared to be a classic case of predator±prey
population dynamics at the molecular level.
The reports from the Yale and TuÈbingen groupsOften, understanding the manner in which a dynamic
system operates can provide an opportunity to take (Schnell et al., 1997, and Mebatsion et al., 1997, respec-
tively) are highly significant as they represent a leapadvantage selectively of the outcome. Most modern bio-
medical endeavors seek to combat disease processes forward in how we might apply basic understandings of
viral biology to the design of therapies that are capablewith such a guiding principle in mind. One form of this
approach begins by understanding the key aspect(s) of of seeking out and destroying designated cells, in this
case HIV-1. Although the current work is not yet readya pathologic disease processÐbe it a gene product, a
misguided cellular response system, or an infectious for a clinical setting, the research boldly demonstrates
that it isnow possible to reverse the aim of the biochemi-viral disease. Biopharmaceuticals seek to restore the
body's natural functioning by targeting the defective cal grappling hooks HIV-1 uses to enter cells and to
employ them against the virus itself. One advantage ofgene or cell system with a drug or gene therapy, or
by some other innovative manipulation of the body's the approach is that it should be difficult for HIV-1, even
with its prodigious mutation rate, to sidestep an assaultphysiology. The challenge is to target the drug or therapy
selectively to the place where it does the most good that employs the exact chemical cues HIV-1 seeks on
target cellsÐsince such escape mutations would impairand creates the fewest side effects. In the arena of phar-
maceutical design encompassing chemotherapy against HIV-1's ability to enter the immune system cells it must
defeat in order to remain pathogenic. The therapeuticviruses or cancers, this general schema is termed ªselec-
tive toxicity.º possibilities go beyond the delivery of engineered vi-
ruses, noteworthy as that is, and suggest immediateTwo groups apply such a philosophy in this issue of
Cell with reports of anti-HIV-1 strategies that use, rather applications that directly deliver drug candidates only
to cells expressing markers of HIV-1 infection. These,than drugs, sophisticatedly engineered viruses capable
of specifically seeking out and killing human cells that and other matters, are discussed below.
Coreceptors: Determinants of HIV-1 Entrydisplay markers of HIV-1 infection (Mebatsion et al.,
1997; Schnell et al., 1997). Perhaps more remarkable, to Immune Cells
A viral infection is in essence a mobile genetic diseasethe engineered hunter±seeker viruses they create are
derived from domesticated versions of an ancient en- that parasitizes host cellular machinery for the purpose
of the virus' own replication. HIV-1 begins infection ofemy of humanityÐthe Rabies virus (family Rhabdoviri-
dae in the order Mononegavirales) and a Rabies viral a cell by recognizing specific ªcoreceptor complexesº
on the surfaces of T cells or macrophages. HIV-1 bindsrelative, the vesicular stomatitus virus (VSV). Certain of
these engineered Rhabdoviruses deliver genes only to to this cellular coreceptor complex via a protein, termed
gp120, found at the membrane surface of the virus, (seeHIV-1-infected target cells, but not to healthy bystander
cells. In one case the engineered Rhabdovirus was ca- Figure 1 for details), allowing physical association of the
virus with the target cell. After binding the coreceptor,pable of preferential self-replication in, and destruction
of, HIV-1-infected cells only. Thus, in a unique sense gp120 signals another protein in the viral membrane,
Figure 1. Pseudotyping of Rhabdoviral Vec-
tors with Human Coreceptors
In the top left, HIV-1 infects a cell using the
viral proteins gp120 and gp41 (both in red,
shown as a monomer) by binding via a core-
ceptor complex of CD4 and a chemokine re-
ceptor (both colored in blue). Binding acti-
vates fusion of the virus with the cell, resulting
in infection. In the right bottom, an engi-
neered Rhabdovirus binds to an HIV-1-
infected cell by incorporation of the same
coreceptor complex (blue) into the Rhabdovi-
ral envelope. Binding to gp120/gp41also initi-
ates fusion, but this time allowing the engi-
neered virus access to the HIV-1 infected cell,
resulting in infection by the Rhabdovirus and
death of the cell.
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called gp41, to activate a rod-like ªfusion domainº struc- other than that of HIV-1 to initiate a membrane fusion
event.ture that pierces the membrane of the target cell and
allows the viral membrane to fuse with the cell mem- The approaches detailed by the Yale and TuÈbingen
groups (Schnell et al., 1997; Mebatsion et al., 1997) tookbrane (Chan et al., 1997; Weissenhorn et al., 1997). By
this action HIV-1 breaches the cell's primary wall of this understanding to a directed conclusion by replacing
the normal viral envelope protein of certain Rhabdovi-defense and injects its core proteins and genetic infor-
mation into the cell. From here, reverse transcription, ruses with a human coreceptor complex, in this case
CD4 and the chemokine receptor CXCR4. Incorporationviral integration, and HIV-1 gene expression can com-
mence and viral replication can ensue. of these proteins into the membrane of an engineered
Rhabdovirus now compelled its binding to, and infectionNew understandings of the coreceptor complex to
which HIV-1 binds on human cells is the essence that of, only those cells expressing HIV-1 gp120 and gp41.
In essence, the coreceptor complex in the engineereddrives the experiments in thecurrent reports. Each core-
ceptor complex has one constant protein, the surface virus membrane is used as bait for gp120/gp41. Those
cells about to release new HIV-1 virions, which are byglycoprotein CD4, and one ªvariableº component, called
a chemokine receptor. As the constant member of the necessity expressing gp120/gp41, take the bait by bind-
ing the coreceptors embedded in the engineered viruscoreceptor complex, CD4 has been long-known as a
primary binding target of the HIV-1 gp120 envelope pro- membranes and fuse with them. Thus, the hunter±seeker
virus enters the cell, whereupon it replicates within ittein. CD4 is expressed on certain subclasses of T cells
and macrophages, acting as the common anchor for and can be caused to destroy that cell alone.
The difficult part of the experiment was coaxing thegp120 recognition of target cells. The variable compo-
nent is drawn from a family of proteins termed ªchemo- Rhabdovirus to incorporate sufficient levels of the core-
ceptors to initiate binding to target cells expressingkine receptors.º The specificity of different HIV-1 iso-
lates to preferentially replicate within primary CD41 T gp120/gp41. The Yale and TuÈbingen (Schnell et al., 1997;
Mebatsion et al., 1997) groups went about this in differ-cells (so-called T-tropic strains of HIV-1), or primary
macrophages and CD41 T cells (M-tropic HIV-1 strains), ent ways based upon significant historical perspectives.
Varmus and colleagues had previously shown that CD4or other cell types is determined by regions of the viral
envelope that can specifically bind one ªvariable com- could be incorporated into the membranes of a retrovi-
rus called avian leukosis virus and had proposed thatponentº chemokine receptor but not another (Moore,
1997; Broder and Collman,1997). Strains of HIV-1 having this might be a technique by which one could deliver
genes specifically to HIV-1-infected cells (Young et al.,T-tropic envelope proteins use CD4 plus the chemokine
receptor CXCR4 (expressed primarily on T cells), whereas 1990). Although the role of the chemokine receptors
had not been fully appreciated at the time, those earlierM-tropic envelope proteins use CD4 along with the
chemokine receptor called CCR5 (expressed mainly on experiments, along with the results of many others,
showed that viruses were not always selective in whatmacrophages and T cells, see Moore, 1997; Broder and
Collman, 1997). Other strains of HIV-1 have more flexible they allowed to mingle with their own envelope proteins
in the lipid bilayer of their membranes.cellular host ranges and use CD4 plus chemokine recep-
tors such as CCR2b or CCR3. The normal function of Given this, the TuÈ bingen group (Mebatsion et al., 1997)
set about an approach in which they created cells thatchemokine receptors in the body is to respond to the
binding of specialized small soluble proteins, termed expressed high levels of a coreceptor protein pair, in
this case CXCR4 chemokine receptor and CD4. Then,chemokines, by inducing immune system cells to mobi-
lize toward the source of the chemokine (Murphy, 1996). they introduced into these cells a Rhabdovirus (in this
case a Rabies virus) that had been made defective byWith these elements of the mechanism understood,
and with newly enabled techniques to engineer, at the deletion of its own envelope protein (termed the G pro-
tein). As wild-type Rhabdoviral replication proceeds,molecular level, the genome and envelope constituents
of another virus group, namely the Rhabdoviridae (Con- completing in as little as 4 hr and killing the cell, it
culminates with its nucleoprotein core budding from thezelmann, 1996), the stage is set for specific targeting of
HIV-1-infected cells by engineered delivery devices. cell, carrying with it cellular membrane material as a
protective sheath. In that membrane is the viral G pro-Switch and Bait: Coreceptor Complexes in
Viral Membranes Allow Engineered Cell tein, concentrated by its association with Rhabdoviral
core proteins during Rhabdoviral assembly, as well asEntry via HIV-1 gp120/gp41
From a physical point of view, the process of fusion of certain other cellular proteins that might be resident in
the cell membrane at the time. In the TuÈbingen experi-two membranes should be independent of whether the
gp120/gp41 partners are on the viral membrane or on ment, as the Rhabdoviral nucleoprotein core exits the
cell, it ªmistakenlyº carries with it low levels of the core-the cell membrane. Simple binding by gp120/gp41 in a
membrane of a target coreceptor complex, such as CD4 ceptors that Mebatsion and colleagues (1997) placed in
the cell membrane. Since their engineered virus doesand CXCR4, in another membrane should initiate the
fusion event. Indeed, nearly a decade ago it was ob- not have G protein to allow entry to target cells, the
only way it can enter a target cell would be to use theserved that as syncytia-inducing HIV-1 strains under-
went lytic replication and viral burst from cells, cell coreceptors that ªcame along for the ride.º As predicted,
the viruses specifically infected cells that were express-membranes could be observed to be undergoing ªself-
fusionº with characteristic membrane blebbing and ac- ing the HIV-1 gp120/gp41 envelope proteins on the cell
surface but not cells that did not express gp120/gp41.companied cell±cell fusion. Therefore, it has been long
understood that gp120/gp41 could be on membranes These viruses could only infect cells for a single round.
Minireview
823
Although the Rhabdoviruses entered the gp120/gp41- might such viruses effect the health of a severely immu-
nocompromised patient? What would happen if such aexpressing cells, they possessed no ability to express
any new envelope protein whatsoever and viral replica- virus were transferred accidentally by a treated HIV-1
patient to another individual, HIV-1 infected or not, whotion ceased with that cell, terminating the experiment.
The authors later enhanced the efficiency of single- has not agreed to receive the therapy? Would one ever
treat a pregnant patient? Is it possible to introduce ªgov-round infection by concentrating in the viral membrane
the chemokine receptor and CD4 by further engineering ernorº controls into such a virus to limit its spread and
effect beyond the cells intended?them to contain those features of the G protein tail that
facilitates G protein assembly into mature Rhabies virus Thus, even if not readily transferred from one person
to another, any use of a self-replicating ªdrugº requiresparticles. The results of the report are important not only
for the specificity of the targetting effect itself. The data levels of governmental approval that should go to the
highest levels of ethical and medical review. There arealso demonstrates that understanding viral assembly
processes can provide directions by which one might far more questions that need to be asked beyond those
addressed in the space here. Given this, however, theenhance the efficiency of the targeting process through
concentrating the coreceptors into the engineered virus results do point in a number of fascinating directions
and lead to obvious approaches that fall far short of theenvelope.
The report by Schnell and colleagues (1997) took this a use of viruses themselves, opening therapeutic ad-
vances that can have near-term applications.step further by creating viruses that killed HIV-1-infected
cells and then acted as self-replicating watchguards For instance, one could consider creating nonviral
delivery devices, or packets, that have embedded inagainst further HIV-1 spread. These workers engineered
a relative of the Rabies virus, VSV, by replacing its G their membranes coreceptor complexes that bind the
different HIV-1 gp120/gp41 envelope variants. Withinenvelope protein with expression cassettes for CD4 and
CXCR4. Thus, cells infected with such an engineered these devices (encased in synthetic membranes called
liposomes) could be anti-HIV-1 drugs with a variety ofvirus express all the structural core proteins of VSV as
well as the coreceptor pair CD4 and CXCR4. This pro- purposes. This would overcome previous difficulties
with liposomes that arose from their lack of specificityvided an enhanced abilityÐan engineered virus that was
not only capable of infecting and destroying a cell ex- and low efficiency of fusion, since coreceptor embed-
ding incorporates a self-loaded specificity element andpressing HIV-1 envelope protein, but that also propa-
gates through the culture carrying a new determinant fusion trigger. One could deliver drugs this way that
kill HIV-1-infected cells or in some other manner inhibitof infection (CD4 and CXCR4), continuouslly killing any
cells that might dare to express HIV-1 envelope protein. replication of HIV-1. This has merit since many anti-
HIV-1 drugs have serious side effects that can debilitateIn one fascinating experiment, the authors show that a
T cell culture infected with both HIV-1 and engineered cells that are not infected. Thus, the broad concept
of selective toxicity again comes into play. One canRhabdoviral particles rapidly converted to a culture of
cells that dropped infectious HIV-1 levels nearly 1000- selectively deliver a drug only to those cells that have
HIV-1, thereby avoiding many of the nastier side effectsfold. Minor low-level ªburstsº of HIV-1 replication that
occurred over a 30-day period were apparently rapidly of the drug.
It is even possible to create simple nonviral liposomesuppressedby remainingengineered virus in theculture.
Presumably, in some rare cells HIV-1 had not activated devices of this nature that incorporate several HIV-1
chemokine receptors along with CD4 to target all cellgp120/gp41 to an extent that allowed detection by the
engineered VSV virus. However, when HIV-1 ªfully acti- types infected expressing gp120/gp41 (one must be
careful to consider uninfected cells that might somehowvatedº in those cells, they presumably were detected
and destroyed by the engineered VSV. It will be impor- acquire gp120/gp41 adventitiously). Cell-free HIV-1 par-
ticles in solution could also be targeted and infused withtant at some later date to determine, and lower, the level
of gp120/gp41 required to initiate binding coreceptor toxins, essentially delivering an HIV-1 ªdisinfectantº that
disables its ability to even enter a cell or replicate there.expressing engineered particles to catch HIV-1 as early
in its burst phase as possible. Could blood supply products be made more safe by
such cleansing agents? Could a specially engineeredProspects for Viraceuticals: Merging the
Concepts of Viral Biology with coreceptor complex, delivered as free protein, be used
to bind to free or budding virus, block its ability to enterPharmaceutical Design?
As important as these results are in terms of specifically new cells, or trigger its natural clearance by the immune
system without the use of any drugs or toxins at all?targeting HIV-1-infected cells, is the approach ready
for use in patients? Are we ready to use one group Such approaches could avoid the issues of a self-repli-
cating virus as drug and might gain rapid approval inof replication-competent viral pathogens to fight the
ravages of another? Are we even ready to use single- medical and ethical circles for more immediate applica-
tion in patients. Since so many different guns can nowround delivery of replication-incompetent virus to kill
HIV-1-infected cells? The answer at this early juncture be aimedÐat a target that HIV-1 cannot readily mutate
from viewÐthe possibilities raised are exciting indeed.is clearly no, that more work needs to be done to under-
stand the implications of the results. For instance, it is Summary
We are a step closer to goals of creating engineeredcritical to consider the multiple potential outcomes of
introducing a novel replicating virus into the environ- viruses and nonviral devices for selective delivery of
pharmaceuticals to HIV-1-infected cells. The viral ap-ment, even if such a virus is intended only for the ªenvi-
ronmentº of a patient and has a therapeutic intent. How proaches must still be considered experimental and
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should be given significant review before their use, if
ever, in humans. However, they point to a variety of
nonviral applications with the prospect of safely deliv-
ering drug candidates to HIV-1-infected cells or cell-
free HIV-1. Since others have previously designed vi-
ruses that preferentially replicate in cancer cells or have
created targeting approaches for other drugs (Bischoff
et al., 1996), the merging of the fields of pharmaceuticals
with delivery approaches gleaned from studying viral
entry is fertile ground for advances against many other
diseases. Future applications could involve evolving
drugs or targeting specificities using viruses in the test
tube, by applying straightforward genetic principles,
that can specifically act against a given disease process
and then use nonviral derivatives, or safe viral ap-
proaches, for use in humans. The insights provided by
the Yale and TuÈbingen groups point to methods of en-
hancing drug specificities that would be well-appreci-
ated by classical pharmacologists and provide a power-
ful set of specific therapeutics. It now remains to be
seen whether we are up to the challenge of appropriately
administering and taking advantage of them.
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